University of Groningen
Through ketamine fields
Viana Chaves, Tharcila
DOI:
10.33612/diss.107955714
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Viana Chaves, T. (2019). Through ketamine fields: pain and afterglow. Rijksuniversiteit Groningen.
https://doi.org/10.33612/diss.107955714
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
PROPOSITIONS
from the PhD thesis
Through ketamine fields
by Tharcila Chaves
1. With a fascinating history, the designed drug ketamine is much more useful to human and veterinary medicines than its current authorised applications. Definitely, ketamine is not just a horse tranquiliser.
2. Ketamine is unique in taking a person out of suicidal thoughts. A 40-minute intravenous infusion is effective for suicidality, something no other officially approved substance can do (chapters 2, 3, 4 and 5, this thesis).
3. Ketamine is the racemate of S-ketamine and R-ketamine. In the United States, a pharmaceutical company is marketing an intranasal spray of S-ketamine for the management of treatment-resistant depression at sky high prices, claiming that it is a different and safer compound, even though this information has not a robust scientific background (chapter 5, this thesis). 4. Ketamine reduces the doses of opiates in the management of chronic pain. It
is another valuable application of ketamine, considering the low safety profile of opiates (chapter 7, this thesis).
5. The ketamine clinics are the first legal modern psychedelic clinics (chapter 5, this thesis).
6. Ketamine is a hype recreational drug worldwide. Ketamine users can develop dependence to it. Therefore, educational and harm reduction campaigns are highly important and necessary for public health (chapters 4 and 6, this thesis). 7. The use of ketamine in a medical setting is safe, with extensive scientific literature
describing its safety profile, even in children (chapters 2 and 6, this thesis). 8. Abstaining people who are not responsive to the conventional treatments
for chronic pain and/or depression from having a try with ketamine is a misguided decision. Ketamine has proven to be a useful and safe therapeutic option for decades. It is time for more compassion.
